Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
January 24, 2019 6:59 AM ESTIncreases Fourth Quarter Revenues 10% to $6.0 Billion, 9% for Full Year to $22.6 Billion Posts Fourth Quarter GAAP EPS of $0.73 and Non-GAAP EPS of $0.94 Announces Strategic Acquisition of Celgene Corporation Announces Voluntary Withdrawal of U.S. Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Lung Cancer in Patients with Tumor Mutational Burden 10 Mutations/Megabase, following discussions with the U.S. FDA Additional Opdivo Plus Yervoy Approvals in Europe for Patients with Renal Cell Carcinoma... More
